Board of Directors
Trevor J. Brown Chairman
In 1994, after 25 years in the Pharmaceutical Industry, which culminated as the Divisional Head of Medical Science Liaison at Upjohn, Trevor founded Premark Services, a strategic marketing consultancy. An MBA at City University Business School focused on pharmaceutical marketing and development strategy and his consultancy went on to specialise in providing innovative solutions for new product research, development and marketing. A specific focus on understanding the unmet medical needs of patients led to a series of epidemiology research projects which resulted in journal publications by expert physician collaborators. Researching to understand the priorities of those who fund healthcare led to programmes designed to improve patient management algorithms and outcomes, and manage costs.
Trevor is currently the Chairman of Shermanbury Parish Council which represents the needs and wants of the residents of Shermanbury Parish; planning future housing developments and the maintenance of existing facilities. He is also a Trustee and Director of the League of the Helping Hand a national UK charity providing financial assistance to those in distress due to illness and circumstances beyond their control.
William C. Stewart, MD
Dr. Stewart is co-founder, CEO and Medical Director of PRN Pharmaceutical Research Network, LLC. With an extensive knowledge in ophthalmic clinical practice, clinical research, pharmaceutical development and financing, Dr. Stewart’s company has a successful track record of supporting research initiatives, for both new and established companies, within the ophthalmology space.
Dr. Stewart is also co-founder of PRN PharmaFarm, LLC.
Dr. Stewart served on the Board of Directors of Encore vision, and was directly involved with the development of their novel presbyopia product, which was successfully licensed to Novartis.
As a researcher, Dr. Stewart has been a principal investigator in numerous ophthalmic studies. He is the author of a medical text, Clinical Practice of Glaucoma (Slack, Inc, 1990), and is a contributing author to 11 ophthalmology texts and monographs. Dr. Stewart has published over 400 peer reviewed articles and letters primarily on the diagnosis and treatment of glaucoma in leading medical journals. He has given over 400 invited lectures at worldwide medical forums in 45 countries. He currently publishes in the area of ophthalmic start-up business and development.
Dr. Stewart received his B.A. in Chemistry from Southern Methodist University and his medical degree from Southwestern Medical School in Dallas, Texas. After finishing a residency in ophthalmology at the University of Missouri at Kansas City, he completed a glaucoma fellowship at Duke University Medical Center under renowned glaucoma thought leader, Dr. M. Bruce Shields.
Daniel is an entrepreneur, investor and advisor in the Life Science and Food industry.
He has co-founded two companies and spent almost 4 years as an Executive-in-Residence at TVM Capital Life Science in Munich. In this role he reviewed hundreds of investment opportunities, closed a large pre-IPO investment with subsequent IPO and served on the Board of Directors of three portfolio companies.
Before that, he spent 12 years at Novartis AG in three different Divisions: Pharma, Vaccines & Diagnostics and Sandoz. Roles included Global Franchise Head, Strategic Marketing Immunology & Infectious Diseases, Global Head of Development and Global Head, New Product & Portfolio Strategy Biopharmaceuticals. During his tenure, he oversaw and was a team member for multiple collaborations, licensing deals and acquisitions from academic to multi-billion-dollar transactions, world-wide commercial launches and FDA / EMA / CFDA / ANVISA registrations with respective global clinical trials.
Prior to Novartis he was at McKinsey & Company, Inc. in Germany, trained as an MD at Johannes-Gutenberg-University Mainz, Germany with clinical training in Germany, Switzerland and the USA (UC Davis Medical Center, Sacramento, CA) and was a scientific co-worker at the Institute for Occupational, Social and Environmental Medicine in Mainz for several years.
Currently Senior Vice President, Commercial, at Novo Nordisk Inc. He is responsible for leading commercial operations in the United States, including sales, marketing and other areas to enhance growth and patient reach.
Brian is an accomplished pharmaceutical executive with over 20 years of global and domestic experience at Novo Nordisk developing and executing strategy.
Before joining Novo Nordisk Inc. in 2019, he was President of Novo Nordisk Canada. As President he significantly increased investment in Canada, launched several innovative products in the therapy areas of diabetes, obesity and hemophilia, and the company was recognized as one of the country’s top 100 employers. He was also a very active contributor on the Boards of Innovative Medicine Canada and BIOTECanada and was frequent spokesperson on behalf of the industry.
Prior to his work at Novo Nordisk Canada, Mr. Hilberdink was a Corporate Vice President in Global Marketing for Novo Nordisk A/S in Copenhagen, Denmark, leading the launch of the company’s futures insulin portfolio; at the time, this represented the single largest investment that had ever been made in diabetes drug development.